161
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Towards a More Patient-Centric Assessment of Immunogenicity for Low-Risk Biologics in Immuno-Oncology Clinical Trials

, , &
Pages 1309-1312 | Received 09 Aug 2021, Accepted 26 Aug 2021, Published online: 02 Sep 2021
 

Acknowledgments

The authorswould like to thank DrOlgaKavetska for reviewing this manuscript.

Disclaimer

The views expressed in this article are those of the authors and do not reflect official policy of Pfizer.

Financial & competing interests disclosure

The authors are employed by Pfizer, Inc., which is involved in development of cancer immunotherapy products. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 346.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.